Neovasc is Creating
Innovative Solutions
for the Treatment of
Advanced Heart Disease
PR Martine Gilard de la Société Française de Cardiologie annonce le lancement officiel du registre « France Réducteur ».
A LEADER IN CARDIOVASCULAR INNOVATION
The company is committed to clinical rigor and collaborates with researchers and clinicians in Canada, the United States, Europe, and the Middle East. Our products, the Reducer™ and Tiara™ systems, represent the forefront of innovation in treating advanced heart disease.
Reducer is CE-marked for use in the EU and is FDA approved for investigational use in the US. Tiara is not commercially available and is currently being evaluated in two ongoing clinical trials.
Headquartered in Vancouver, BC and Minneapolis, MN, Neovasc is publicly traded on both the NASDAQ and the Toronto Stock Exchange (NVCN).
LEADERSHIP AND GUIDANCE
President and Chief Executive Officer
Chief Operating Officer
Chief Financial Officer
Vice President of Regulatory Affairs
Global Angina Therapies
Vice President of Clinical Affairs
Chief Quality Officer
MD, Medical Director
Fred Colen
President and Chief Executive Officer

Bill Little
Chief Operating Officer

Christopher Clark
Chief Financial Officer

Lisa Becker
Vice President of Regulatory Affairs
Global Angina Therapies

Sarah Gallagher
Vice President of Clinical Affairs

John Panton
Chief Quality Officer

Prof. Shmuel Banai
MD, Medical Director
